Rosen Law Firm Urges Microvast Investors to Act by September 21
News related to:Microvast Holdings, Inc · 1 min read
NEW YORK, Sept. 19, 2026 /CourierPR/ -- Rosen Law Firm, a global investor rights law firm, is reminding investors in Microvast Holdings, Inc. (NASDAQ: MVST) of an important deadline. The firm is urging investors who purchased Microvast securities between April 1, 2025, and March 16, 2026, inclusive, to secure legal counsel before the September 21, 2026, lead plaintiff deadline.
According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) due to, inter alia, inventory management issues and delays in commercial vehicle rollouts by Microvast’s customers, defendants had overstated Microvast’s ability to reach its margin targets; (2) defendants overstated Microvast’s ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
Rosen Law Firm has a track record of success in leadership roles. The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements it has achieved. Since 2013, the firm has been ranked in the top 4 each year and has recovered billions of dollars for investors. In 2019 alone, Rosen Law Firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of the Plaintiffs' Bar.
The firm's website also provides additional resources and information for investors. You can follow the Rosen Law Firm for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm, or on Facebook: https://www.facebook.com/rosenlawfirm/.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.